Clinical Trial Update: Comparative Bioavailability Between Two Tramadol Formulations: Study of the Better Controlled Release of a New 200 mg Once A Day (OAD) Formulation Versus Zytram® 200 mg [Phase 1]

View source ↗

Summary

Phase 1 bioavailability study comparing a new 200 mg once-daily controlled-release tramadol formulation to Zytram 200 mg; results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• New 200 mg once-daily controlled-release tramadol (tramadol hydrochloride)
• Zytram 200 mg (tramadol hydrochloride)

Snippet

Sponsor: Labopharm Inc. | Conditions: Pain | Phase 1 | Status: COMPLETED | Results posted: 2009-06-02